Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3
John D. Powderly(Carolina BioOncology Institute), Bartosz Chmielowski(UCLA Health), Paul A. Moore(Zymeworks (Canada)), Francine Chen(MacroGenics (United States)), Jan Baughman(University of California System), Jeffrey S. Weber(NYU Langone Health), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Deryk Loo(Ecogenomics (Japan)), Howard A. Burris(Deaconess Hospital), Russell Z. Szmulewitz(University of Chicago), Antoni Ribas(University of California, Los Angeles), Gregory M. Coté(Harvard University), Roger B. Cohen(University of Pennsylvania), Ezio Bonvini(MacroGenics (United States)), James R. Vasselli(The University of Texas MD Anderson Cancer Center), Keith T. Flaherty(Cancer Research Center)
Cited by 101
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.8k